HER-2/Neu alterations in non-small cell lung cancer: A comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry

Caterina Pellegrini, Monica Falleni, Antonio Marchetti, Barbara Cassani, Monica Miozzo, Fiamma Buttitta, Massimo Roncalli, Guido Coggi, Silvano Bosari

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Purpose: Amplification and/or overexpression of HER2/neu have been documented in many types of epithelial tumor, and HER2/neu evaluation is now gaining importance, because this mechanisms of disease can be inhibited in vivo using humanized monoclonal antibodies. The main purpose of our investigation includes the evaluation of the prevalence of HER2/neu alterations in non-small cell lung cancer (NSCLC) at different molecular levels. Experimental Design: We performed a comprehensive investigation of HER2/neu alterations in a series of 115 NSCLC, using fluorescence in situ hybridization (FISH), real time reverse transcription (RT)-PCR, and immunohistochemistry. Results: HER2/neu immunoreactivity was detected in 26 of 115 of specimens (23%), with 5 carcinomas (4%) showing intense staining. Real time RT-PCR demonstrated HER2/ neu mRNA in all samples analyzed, with levels above normal in 54 of 115 of carcinomas (47%). FISH documented HER2/neu gene amplification in 9 of 41 carcinomas (22%). Conclusions: These results demonstrate that HER2/neu alterations occur in NSCLC, albeit with significantly different prevalence depending on the technical assay used for the assessment. It is therefore likely that inhibitory monoclonal antibodies will be appropriate in the treatment of a subgroup of NSCLC patients. The results suggest that other mechanisms unrelated to gene amplification could be responsible for HER2/neu mRNA or protein overexpression. FISH, real time RT-PCR, and immunohistochemistry are complementary techniques for the evaluation of HER2/ neu activation, useful for the identification of the subgroup of patients to be treated. The real time RT-PCR assay is very sensitive and requires minimal amounts of tissue for testing, and additional studies should evaluate its clinical application for patient evaluation.

Original languageEnglish
Pages (from-to)3645-3652
Number of pages8
JournalClinical Cancer Research
Volume9
Issue number10 I
Publication statusPublished - Oct 1 2003

Fingerprint

Fluorescence In Situ Hybridization
Non-Small Cell Lung Carcinoma
Reverse Transcription
Immunohistochemistry
erbB-2 Genes
Polymerase Chain Reaction
Gene Amplification
Carcinoma
Antibodies, Monoclonal, Humanized
Messenger RNA
Research Design
Monoclonal Antibodies
Staining and Labeling
Neoplasms
Proteins
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

HER-2/Neu alterations in non-small cell lung cancer : A comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. / Pellegrini, Caterina; Falleni, Monica; Marchetti, Antonio; Cassani, Barbara; Miozzo, Monica; Buttitta, Fiamma; Roncalli, Massimo; Coggi, Guido; Bosari, Silvano.

In: Clinical Cancer Research, Vol. 9, No. 10 I, 01.10.2003, p. 3645-3652.

Research output: Contribution to journalArticle

@article{6c15dcd94bd94681b4d97d61a5645028,
title = "HER-2/Neu alterations in non-small cell lung cancer: A comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry",
abstract = "Purpose: Amplification and/or overexpression of HER2/neu have been documented in many types of epithelial tumor, and HER2/neu evaluation is now gaining importance, because this mechanisms of disease can be inhibited in vivo using humanized monoclonal antibodies. The main purpose of our investigation includes the evaluation of the prevalence of HER2/neu alterations in non-small cell lung cancer (NSCLC) at different molecular levels. Experimental Design: We performed a comprehensive investigation of HER2/neu alterations in a series of 115 NSCLC, using fluorescence in situ hybridization (FISH), real time reverse transcription (RT)-PCR, and immunohistochemistry. Results: HER2/neu immunoreactivity was detected in 26 of 115 of specimens (23{\%}), with 5 carcinomas (4{\%}) showing intense staining. Real time RT-PCR demonstrated HER2/ neu mRNA in all samples analyzed, with levels above normal in 54 of 115 of carcinomas (47{\%}). FISH documented HER2/neu gene amplification in 9 of 41 carcinomas (22{\%}). Conclusions: These results demonstrate that HER2/neu alterations occur in NSCLC, albeit with significantly different prevalence depending on the technical assay used for the assessment. It is therefore likely that inhibitory monoclonal antibodies will be appropriate in the treatment of a subgroup of NSCLC patients. The results suggest that other mechanisms unrelated to gene amplification could be responsible for HER2/neu mRNA or protein overexpression. FISH, real time RT-PCR, and immunohistochemistry are complementary techniques for the evaluation of HER2/ neu activation, useful for the identification of the subgroup of patients to be treated. The real time RT-PCR assay is very sensitive and requires minimal amounts of tissue for testing, and additional studies should evaluate its clinical application for patient evaluation.",
author = "Caterina Pellegrini and Monica Falleni and Antonio Marchetti and Barbara Cassani and Monica Miozzo and Fiamma Buttitta and Massimo Roncalli and Guido Coggi and Silvano Bosari",
year = "2003",
month = "10",
day = "1",
language = "English",
volume = "9",
pages = "3645--3652",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10 I",

}

TY - JOUR

T1 - HER-2/Neu alterations in non-small cell lung cancer

T2 - A comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry

AU - Pellegrini, Caterina

AU - Falleni, Monica

AU - Marchetti, Antonio

AU - Cassani, Barbara

AU - Miozzo, Monica

AU - Buttitta, Fiamma

AU - Roncalli, Massimo

AU - Coggi, Guido

AU - Bosari, Silvano

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Purpose: Amplification and/or overexpression of HER2/neu have been documented in many types of epithelial tumor, and HER2/neu evaluation is now gaining importance, because this mechanisms of disease can be inhibited in vivo using humanized monoclonal antibodies. The main purpose of our investigation includes the evaluation of the prevalence of HER2/neu alterations in non-small cell lung cancer (NSCLC) at different molecular levels. Experimental Design: We performed a comprehensive investigation of HER2/neu alterations in a series of 115 NSCLC, using fluorescence in situ hybridization (FISH), real time reverse transcription (RT)-PCR, and immunohistochemistry. Results: HER2/neu immunoreactivity was detected in 26 of 115 of specimens (23%), with 5 carcinomas (4%) showing intense staining. Real time RT-PCR demonstrated HER2/ neu mRNA in all samples analyzed, with levels above normal in 54 of 115 of carcinomas (47%). FISH documented HER2/neu gene amplification in 9 of 41 carcinomas (22%). Conclusions: These results demonstrate that HER2/neu alterations occur in NSCLC, albeit with significantly different prevalence depending on the technical assay used for the assessment. It is therefore likely that inhibitory monoclonal antibodies will be appropriate in the treatment of a subgroup of NSCLC patients. The results suggest that other mechanisms unrelated to gene amplification could be responsible for HER2/neu mRNA or protein overexpression. FISH, real time RT-PCR, and immunohistochemistry are complementary techniques for the evaluation of HER2/ neu activation, useful for the identification of the subgroup of patients to be treated. The real time RT-PCR assay is very sensitive and requires minimal amounts of tissue for testing, and additional studies should evaluate its clinical application for patient evaluation.

AB - Purpose: Amplification and/or overexpression of HER2/neu have been documented in many types of epithelial tumor, and HER2/neu evaluation is now gaining importance, because this mechanisms of disease can be inhibited in vivo using humanized monoclonal antibodies. The main purpose of our investigation includes the evaluation of the prevalence of HER2/neu alterations in non-small cell lung cancer (NSCLC) at different molecular levels. Experimental Design: We performed a comprehensive investigation of HER2/neu alterations in a series of 115 NSCLC, using fluorescence in situ hybridization (FISH), real time reverse transcription (RT)-PCR, and immunohistochemistry. Results: HER2/neu immunoreactivity was detected in 26 of 115 of specimens (23%), with 5 carcinomas (4%) showing intense staining. Real time RT-PCR demonstrated HER2/ neu mRNA in all samples analyzed, with levels above normal in 54 of 115 of carcinomas (47%). FISH documented HER2/neu gene amplification in 9 of 41 carcinomas (22%). Conclusions: These results demonstrate that HER2/neu alterations occur in NSCLC, albeit with significantly different prevalence depending on the technical assay used for the assessment. It is therefore likely that inhibitory monoclonal antibodies will be appropriate in the treatment of a subgroup of NSCLC patients. The results suggest that other mechanisms unrelated to gene amplification could be responsible for HER2/neu mRNA or protein overexpression. FISH, real time RT-PCR, and immunohistochemistry are complementary techniques for the evaluation of HER2/ neu activation, useful for the identification of the subgroup of patients to be treated. The real time RT-PCR assay is very sensitive and requires minimal amounts of tissue for testing, and additional studies should evaluate its clinical application for patient evaluation.

UR - http://www.scopus.com/inward/record.url?scp=0141456467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141456467&partnerID=8YFLogxK

M3 - Article

C2 - 14506153

AN - SCOPUS:0141456467

VL - 9

SP - 3645

EP - 3652

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10 I

ER -